RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced a partnership with Great Lakes Medical Laboratory, Inc. (GLML), a full-service medical reference laboratory, to offer its AditxtScore™ for COVID-19 throughout the State of Michigan. The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutralizing antibody responses against several different antigens. This makes it possible to assess the strength of an individual’s immune response to the SARS-CoV-2 virus.
Under the agreement, GLML will make the AditxtScore for COVID-19 available throughout its six physical locations and mobile units in Michigan. The initiative is part of Aditxt’s ongoing effort to expand its immune monitoring network nationwide.
“We were drawn to Aditxt initially because it has the most comprehensive COVID-19 immune testing solution available, allowing us to give people clarity about their individual immune response to COVID-19,” said Elizabeth Knisely, Chief Executive Officer of GLML. “What I did not expect was that after receiving an AditxtScore myself I would find that I had low immune response, despite being vaccinated. With so much uncertainty out there right now around a surge in breakthrough cases, we need to take the guesswork out of the equation especially for patients who are vulnerable and immunocompromised.”
AditxtScore for COVID-19, which was first introduced in August 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual’s immune response to multiple antigens associated with COVID-19. This multiplex approach to capturing the full spectrum of biomarkers associated with COVID-19 delivers a highly detailed snapshot of an individual’s immune response in a single test cycle. It also includes the ability to measure neutralizing antibodies, the subset of virus-specific antibodies that block infection by interfering with cell entry of virus particles. The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM and IgA isotopes, can provide clinicians with the data they need to understand the strength and quality of each individual’s immune response to COVID-19.
“While we have seen an increase in the number of COVID-19 vaccines administered in Michigan, just under half of our population is still not vaccinated and vaccine hesitancy remains a significant challenge in our rural and urban areas,” said Samar Nasry, MD, internal medicine specialist and Director of the Medical Care1 Urgent Care in Michigan. “A lot of the hesitancy we’re seeing is driven by misinformation, potential infection post vaccination, and uncertainty about individual risk. The wide availability of the AditxtScore for COVID-19 will help us address those challenges by giving people the hard facts about their immune status.”
This information is particularly important for the millions of immunocompromised patients who may not develop an adequate immune response to vaccination or exposure for multiple reasons, including: immunosuppressive disease, immunosuppressant medications, anti-cancer medications affecting immune function, or the presence of long-term chronic disease that has exhausted the body’s natural immune response capacity.
“We’re thrilled to be working with GLML to bring our AditxtScore for COVID-19 to the state of Michigan,” said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. “Everyone’s immune response is unique to that individual, so it’s critical to evaluate each individual’s immune response in order to effectively address this pandemic. Our AditxtScore for COVID-19 delivers that personalized approach with the accessibility and efficiency needed to scale.”
AditxtScore for COVID-19 is offered through authorized channel partners. To find an AditxtScore Channel Partner near you, please visit www.aditxtscore.com. AditxtScore for COVID-19 is available for use as a CLIA-validated laboratory developed test (LDT). This test is not for self-diagnosis and is not cleared or approved by the FDA.
About Aditxt:
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt’s immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.